



INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/750,326
	Filing Date	December 31, 2003
	First Named Inventor	Jeffrey O. Saunders
	Group Art Unit	4714 1624
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	VPI/02-142 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
TNT	B1	WO	95/15963	BASF Aktiengesellschaft	15 June 1995		
	B2	WO	98/18781	Versicor, Inc.	7 May 1998		
	B3	WO	98/56770	BASF Aktiengesellschaft	17 December 1998		
TNT	B4	EP	0 456 835	Kyorin Pharmaceutical Co., Ltd.	21 November 1991		

OTHER NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
TNT	C1	Malamas, et al., "Quinazolineacetic Acids and Related Analogues as Aldose Reductase Inhibitors", J. Med. Chem., Vol. 34, No. 4, pp. 1492-1503 (1991).
TNT	C2	Gordeev, et al., "A General and Efficient Solid Phase Synthesis of Quinazoline-2,4-diones.", Tetrahedron Letters, Vo. 38, No. 10, pp. 1729 -1732 (1997).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	7/10/06
--------------------	--	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.